<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199186</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571ADE10</org_study_id>
    <secondary_id>GMALL-STI571-ELDERLY-01/02</secondary_id>
    <nct_id>NCT00199186</nct_id>
  </id_info>
  <brief_title>Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>A Randomized, Multicenter Open Label Phase II Study to Determine the Safety and Efficacy of Induction Therapy With Imatinib in Comparison With Standard Induction Chemotherapy in Elderly (&gt; 55 Years) Patients With Ph Positive Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <brief_summary>
    <textblock>
      The aims of the study are to determine whether single agent imatinib (STI571; Glivec) is more
      effective as up-front remission induction therapy than conventional multi-agent induction
      chemotherapy for elderly patients with Philadelphia positive (Ph+)ALL, whether this treatment
      is better tolerated, and whether subsequent combination therapy with imatinib and
      chemotherapy of approximately a 1 year duration is tolerable and effective with respect to
      maintaining remissions.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate after induction therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate during induction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events during induction</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of salvage therapy after crossover</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of minimal residual disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of point mutations in the BCR-ABL gene</measure>
  </secondary_outcome>
  <condition>Philadelphia Positive Acute Lymphoblastic Leukemia</condition>
  <condition>Lymphoid Blastic Phase of Chronic Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytosine arabinoside</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate (intrathecal)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AraC (intrathecal)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone (intrathecal)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients

          -  Age &gt; 55 years (biological age)

          -  Diagnosis of Ph1 chromosome-positive ALL (pre-B, common- or pre-pre-B ALL)

          -  Newly diagnosed, lymphoid blast crisis of chronic myeloid leukemia

          -  Only pre-phase chemotherapy prior to study start

          -  World Health Organization (WHO) status 0, 1 or 2

          -  Voluntary written informed consent

        Exclusion Criteria:

          -  Creatinine levels more than 2 x the upper limit of normal (ULN)

          -  Total serum bilirubin more than 1.5 x the ULN

          -  AST (SGOT) or ALT (SGPT) more than 5 x the ULN

          -  Any other prior antineoplastic treatment except for pre-phase chemotherapy

          -  Active central nervous system (CNS) leukemia

          -  New York Heart Association (NYHA) grade 3/4 cardiac disease

          -  Active severe infection

          -  Serious concomitant medical condition

          -  Patients with a history of non-compliance to medical regimens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver G Ottmann, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Medizinische Klinik II, Johann Wolfgang Goethe Universität</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver G Ottmann, M.D.</last_name>
    <phone>++49-69-6301-0</phone>
    <phone_ext>6221</phone_ext>
    <email>ottmann@em.uni-frankfurt.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Wassmann, M.D.</last_name>
    <phone>++49-69-6301-0</phone>
    <phone_ext>6221</phone_ext>
    <email>wassmann@em.uni-frankfurt.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Klinik II, Johann Wolfgang Goethe Universität</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver G Ottmann, M.D.</last_name>
      <phone>++49-69-6301-0</phone>
      <phone_ext>6221</phone_ext>
      <email>ottmann@em.uni-frankfurt.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 18, 2007</last_update_submitted>
  <last_update_submitted_qc>October 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

